Galapagos and Allergan Enter Drug Discovery Collaboration
News May 06, 2008
Galapagos NV has announced that Galapagos' service division, BioFocus DPI, will provide hit-finding services for multiple Allergan, Inc. targets. Total contract value for Galapagos could reach up to €1.3 million over the next 12 months, contingent on the number of BioFocus DPI compounds screened.
BioFocus DPI's Basel (Allschwil, Switzerland) site has provided drug discovery services for Allergan since 2002. In this new collaboration, BioFocus DPI will provide assay development and high-throughput screening services for several Allergan targets. Furthermore, BioFocus DPI's computational chemists plan to work together with Allergan to select compounds from the Allergan and BioFocus DPI compound libraries for screening against these targets.
"We are pleased to sign another collaboration with Allergan," said Onno van de Stolpe, CEO of Galapagos. "They are an important customer for BioFocus DPI's biology business and having a satisfied customer coming back for more screening is gratifying."